|
TGFBRAP1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.68499658670385E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.98250038186654E-10 |
| Normal-vs-Stage2 |
1.199780E-04 |
| Normal-vs-Stage3 |
1.12279996411502E-09 |
| Normal-vs-Stage4 |
1.12529999762856E-08 |
| Stage1-vs-Stage2 |
5.015600E-01 |
| Stage1-vs-Stage3 |
4.903200E-01 |
| Stage1-vs-Stage4 |
2.372400E-01 |
| Stage2-vs-Stage3 |
2.708800E-01 |
| Stage2-vs-Stage4 |
1.749800E-01 |
| Stage3-vs-Stage4 |
6.203800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.79819525725611E-11 |
| Normal-vs-AfricanAmerican |
7.232300E-04 |
| Normal-vs-Asian |
2.36190000002523E-07 |
| Caucasian-vs-AfricanAmerican |
4.392400E-01 |
| Caucasian-vs-Asian |
6.093800E-01 |
| AfricanAmerican-vs-Asian |
2.735800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.8887008037043E-11 |
| Normal-vs-Female |
3.50889983735669E-10 |
| Male-vs-Female |
1.489600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.1672000012104E-09 |
| Normal-vs-Age(41-60Yrs) |
2.79659961854861E-10 |
| Normal-vs-Age(61-80Yrs) |
3.42710000378332E-08 |
| Normal-vs-Age(81-100Yrs) |
5.844100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.155600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.793600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.686200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.135400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.144200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.119000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.706600E-01 |
| Classical-VS-Follicular |
9.247400E-01 |
| Classical-VS-Other |
4.106300E-02 |
| Classical-VS-Normal |
2.80400036523076E-10 |
| Tall-VS-Follicular |
3.377800E-01 |
| Tall-VS-Other |
1.093440E-01 |
| Tall-VS-Normal |
1.00709999995008E-06 |
| Follicular-VS-Other |
1.054000E-01 |
| Follicular-VS-Normal |
2.24220000000219E-06 |
| Other-VS-Normal |
1.036550E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.65190039003971E-10 |
| Normal-vs-N1 |
1.82000003956517E-09 |
| N0-vs-N1 |
6.600100E-02 |
|
|
